Guowei Yang

Dr. Guowei Yang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JWJuncheng Mbbs Wan
Juncheng Mbbs Wan
BTBufu Tang
Bufu Tang
WZWen Zhang
Wen Zhang
YZYongjie Zhou
Yongjie Zhou
CJChaoqiao Mbbs Jin
Chaoqiao Mbbs Jin
XQXudong Qu
Xudong Qu
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy – combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy – improves outcomes. However, few studies have directly compared this regimen with triple therapy (TACE plus targeted therapy and immunotherapy), and the optimal sequence of locoregional treatments within this regimen remains unclear. Objective: To compare the efficacy and safety of HAIC-first quadruple therapy, TACE-first quadruple therapy, and triple therapy in patients with unresectable HCC (uHCC). Materials and Methods: We retrospectively analyzed 158 patients with uHCC who received: HAIC-first quadruple therapy (HTTI, n = 61), TACE-first quadruple therapy (THTI, n = 41), or triple therapy (TTI, n = 56). Tumor response was assessed with modified RECIST; progression-free survival (PFS), overall survival (OS), and safety were compared. Results: The HTTI group achieved the highest objective response rate (ORR, 81.97%) and disease control rate (DCR, 96.72%), outperforming the THTI (ORR 73.17%, DCR 95.12%) and TTI groups (ORR 64.28%, DCR 85.71%). The median OS (mOS) was not reached in the HTTI group; the THTI group had a longer mOS (22.30 months) than the TTI group (19.00 months, P = 0.046). The median PFS (mPFS) was also longer in the HTTI group (12.90 months), compared to the THTI (10.40 months, P = 0.042) group and TTI groups (9.30 months, P < 0.001). Quadruple therapy increased grade 1 and 2 hypoalbuminemia, thrombocytopenia, and hand-foot syndrome, but grade 3 and 4 toxicities were similar across groups. Conclusion: Quadruple therapy demonstrates superior efficacy compared to triple therapy for uHCC. Initiating treatment with HAIC followed by TACE appears more effective than the reverse sequence and merits prospective validation.

12 August 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ZFzz Fan
zz Fan
BYBowen Yin
Bowen Yin
CXChen Xiaochen
Chen Xiaochen
GYGuowei Yang
Guowei Yang
WZWei Zhang
Wei Zhang
RLRong Liu
Rong Liu
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, characterized by high rates of angiogenesis and immune evasion. Paraspeckle genes, involved in gene regulation and RNA metabolism, have recently been linked to tumor progression. This study aims to elucidate the relationship between paraspeckle genes and HCC prognosis, focusing on SFPQ, DDX39B, and UBAP2. Methods: We analyzed HCC (LIHC) and prostate cancer (PRAD) samples from the TCGA database to explore the correlation between paraspeckle genes and angiogenesis. We conducted unsupervised clustering, risk scoring, and survival analysis to identify distinct patient groups and their clinical outcomes. Gene expression data were used to perform differential analysis and Gene Ontology (GO) enrichment. Results: Our analysis identified significant correlations between paraspeckle genes and angiogenesis across multiple cancer types. Elevated expression levels of SFPQ, DDX39B, and UBAP2 were associated with poor prognosis in HCC patients, and all of them has statistical significance. Unsupervised clustering of HCC samples based on paraspeckle gene expression revealed two distinct clusters, with high-risk patients exhibiting stronger immune suppression and tumor immune evasion. GO enrichment highlighted critical pathways related to angiogenesis and immune regulation. Additionally, a risk scoring model based on these genes effectively distinguished high-risk and low-risk patient groups, providing valuable prognostic insights. Conclusion: This study demonstrates that SFPQ, DDX39B, and UBAP2 are significantly associated with poor prognosis in HCC, likely due to their roles in promoting angiogenesis and immune suppression. These findings highlight the potential of paraspeckle genes as prognostic biomarkers and therapeutic targets, offering new avenues for personalized treatment strategies in HCC. Further research into their functional mechanisms and clinical applicability is crucial for advancing HCC treatment and improving patient outcomes.

1 August 2015
Verified
Journal Article
Closed access
RLRong Liu
Rong Liu
GYGuowei Yang
Guowei Yang
YWYueyan Wu
Yueyan Wu
HRHuiyun Rao
Huiyun Rao
XLXuefu Li
Xuefu Li
PQPingxian Qian
Pingxian Qian

14 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LSLiting Shan
Liting Shan
ZFzz Fan
zz Fan
GYGuowei Yang
Guowei Yang
SQSheng Qian
Sheng Qian
WZWei Zhang
Wei Zhang
RLRong Liu
Rong Liu
Objectives: To compare the therapeutic efficacy and safety of balloon-assisted transarterial chemoembolization (B-TACE) versus conventional TACE (C-TACE) in hepatocellular carcinoma (HCC) and to evaluate the potential predictive value of intraoperative balloon-occluded arterial stump pressure (Boasp). Methods: In this prospective, single-centre, randomized controlled study, 60 patients with hepatocellular carcinoma were allocated to either the B-TACE group (n = 30) or the C-TACE group (n = 30). One patient in the B-TACE group was lost to follow-up after allocation. The primary analyses were conducted according to the intention-to-treat (ITT) principle, including all randomized patients, with conservative handling of missing data. Sensitivity analyses were performed to assess the robustness of the results. Tumor response and survival outcomes were evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Cox proportional hazards regression models. Intraoperative balloon-occluded arterial stump pressure (BOASP) was measured as an exploratory parameter to quantify embolization adequacy. Adverse events (AEs) were systematically assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Results: TACE achieved a higher 3-month ORR (63.3% vs. 10.0%, p < 0.001) and 6-month disease control rates (80.0% vs. 36.7%, p < 0.001), with PFS (HR = 0.30, 95% CI 0.148–0.608) and procedures within 6 months (1 vs. 3, p < 0.001). The 6-month surgical conversion rate was higher (34.5% vs. 6.7%, p = 0.009). Changes in Boasp correlated with efficacy (AUC = 0.825, p = 0.0398). Severe infections were lower in B-TACE (17.2% vs. 76.7%, p < 0.001). Conclusions: B-TACE offers superior efficacy, survival, and surgical conversion versus C-TACE with favorable safety. Boasp provides a quantitative biomarker for predicting treatment response.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
ZFZhuoyang Fan
Zhuoyang Fan
YGYang Gao
Yang Gao
JWJuncheng Wan
Juncheng Wan
YZYiwei Zhu
Yiwei Zhu
MLMing Li
Ming Li
GYGuowei Yang
Guowei Yang
Heat ablation techniques, such as microwave and radiofrequency ablation, are established interventions for hepatocellular carcinoma (HCC). However, incomplete ablation often leads to angiogenesis‐driven metastasis and recurrence, undermining long‐term treatment efficacy. The molecular mechanisms facilitating post‐ablation angiogenesis remain poorly understood. In this study, we identified a marked upregulation of SERPINE1 following sublethal heat treatment, which was corroborated in both rabbit models and human HCC cell lines. Further investigation revealed that SERPINE1 promotes angiogenesis, at least in part, through vascular endothelial growth factor A (VEGFA) activation after sublethal heat exposure. We further delineated that METTL3 and IGF2BP1 regulate SERPINE1 expression via an N6‐methyladenosine (m6A)‐dependent pathway. The proangiogenic role of SERPINE1 was substantiated using patient‐derived HCC organoids and in vivo models, where the small‐molecule inhibitor PAI‐039 significantly attenuated sublethal heat ablation‐induced angiogenesis and tumor proliferation. Our findings illuminate the METTL3/IGF2BP1/SERPINE1/VEGFA axis as a novel therapeutic target for improving HCC heat ablation outcomes. Therapeutically, PAI‐039 emerges as a potent adjunctive agent that could synergistically enhance the efficacy of thermal ablation in HCC management.